Author

George Sharbeen

UNSW SydneyORCID 0000-0002-6373-1930Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

Australian Pancreatic Cancer Genome Initiative· 2 shared Paul TimpsoniD· 2 shared Adnan M. NagrialiD· 1 shared Alexis Ang· 1 shared Alice M. H. Tran· 1 shared Amber Johns· 1 shared Amelia L. ParkeriD· 1 shared Anaiis Zaratzian· 1 shared

Activity by Year

2021-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Australian Pancreatic Cancer Genome Initiative

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintJul 23, 2026

Pulsed priming with the FAK inhibitor narmafotinib enhances both gemcitabine/Abraxane and FOLFIRINOX chemotherapy response in pancreatic cancer

Kendelle Joan Murphy, Cecilia R. Chambers, Daniel A. Reed…·Paul Timpson

This paper shows that pulsed narmafotinib priming improves chemotherapy response in pancreatic cancer by reducing fibrosis and enhancing treatment efficacy.

DOI 10.64898/2026.07.23.740234

humanexperimental assay

𝕏 PostBluesky

Cancer BiologyCancer ResearchPeer-reviewedMay 12, 2021

Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma determine response to SLC7A11 inhibition

George Sharbeen, Joshua A McCarroll, Anouschka Akerman…·Phoebe A Phillips

This study shows that SLC7A11 in pancreatic ductal adenocarcinoma stroma, not tumor cells, predicts poor survival and that inhibiting it reduces CAF activity and tumor growth.

DOI 10.1158/0008-5472.can-20-2496

mousebulk RNA-seq

𝕏 PostBluesky